Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Conference Presentation (February 2024)
21 slides from Cantargia Ab's conference presentation, February 2024
Slide 1: Targeting IL1RAP to address unmet needs in severe cancer and autoimmune diseases
Targeting IL1RAP to address unmet needs in severe cancer and autoimmune diseases Corporate Presentation Feb 2024 NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and
Slide 3: Cantargia – Investment highlights
Cantargia – Investment highlights NOVEL IL1RAP ANTIBODIES, POTENTIAL TO TREAT CANCER & INFLAMMATORY DISEASE • IL1RAP elevated in most solid and liquid tumors • IL1RAP signaling drives several autoimmune and inflammatory diseases NADUNOLIMAB: CLEAR ACTIVITY SIGNALS IN CANCER THERAPY WITH UPCOMING CAT
Slide 4: Current pipeline
Current pipeline Project Disease Type of Discovery Preclinical — Clinical Clinical Clinical ' treatment phase phase phase | phase II phase Ill PDAC 1% line Gemcitabine/nab-paclitaxel Nadunolimab TNBC 15*/2"4 jine Carboplatin/gemcitabine NSCLC/ ' non-squamous NSCLC ine Platinum doublets Systeme se TT
Slide 5: Nadunolimab (CAN04) Overview
NADUNOLIMAB (CAN04) OVERVIEW
Slide 6: IL1RAP overexpressed in most solid tumors
IL1RAP overexpressed in most solid tumors IL1RAP EXPRESSION IN SOLID TUMOR TYPES SEVERAL TUMOR-PROMOTING CELLS EXPRESSING IL1RAP IN THE TUMOR MICROENVIRONMENT 100% IL1RAP-expressing tumors 75% 50% 25% 0% l C C st al ic er er ta SC CL at ge ea Liv d ec ad re NS HN ha Br r nc lo Bl op Co Pa Es Cancer
Slide 7: Targeting IL1RAP provides unique opportunities to treat cancer by IL-1α/β blockade and ADCC
Targeting IL1RAP provides unique opportunities to treat cancer by IL-1α/β blockade and ADCC Nadunolimab NADUNOLIMAB COUNTERACTS IMMUNE SUPPRESSION AND POTENTIATES THERAPY ADCC – Antibody-Dependent Cellular Cytotoxicity; NK – Natural Killer; TIR – Toll-Interleukin-1 Receptor 7
Slide 8: PDAC – Positive interim data in 1st line patients
PDAC – Positive interim data in 1st line patients OS and iPFS for mITT patients Best responses according to iRECIST 50% Best change in tumor size 0% -50% -100% iCPD iUPD iSD iPR Nadunolimab combination with Gem/Abraxane in 1st line PDAC (n=73): → 33% response rate with long OS and iPFS → Additional
Slide 9: PDAC – Strong efficacy in patients with high tumor IL1RAP level
PDAC – Strong efficacy in patients with high tumor IL1RAP level OS by IL1RAP subgroup IL1RAP High IL1RAP Low 50% Best change in tumor size iCPD 0% iUPD iSD iPR -50% -100% Efficacy analysis for IL1RAP High (n=29) vs IL1RAP Low (n=20) PDAC patients (1st line, combination with Gem/Abraxane): → Signific
Slide 10: Nadunolimab PDAC milestone targets
Nadunolimab PDAC milestone targets mid-2024 H1 2025 H2 2025 H1 2026 H1 2027 H1 2028 H2 2028 Start PANFOUR PANFOUR enrolment PANFOUR study study completed results FDA meeting FDA EOP2 meeting Phase III study preparation Start Phase III Phase III enrolment Phase III study study completed results Poten
Slide 11: NSCLC – Complete responders with distinct biomarker profile
NSCLC – Complete responders with distinct biomarker profile 150 Target lesion diameter Nadunolimab monotherapy NCG 100 CR (mm) 50 two lymph nodes reduced to ≤5 mm 0 0 12 24 36 48 Months 100 3 80 Positive cells (%) 60 → One CR maintained over 3 yrs (CR1), second CR Score (0-3) 40 2 PD-L1 (tumor cel
Slide 12: TNBC – Promising early safety and efficacy
TNBC – Promising early safety and efficacy Nadunolimab combination with Best responses according to RECIST OS and PFS Gem/Carbo in 1st/2nd line 100% metastatic TNBC: Best change in tumor size 50% 15 patients enrolled in the dose- escalation phase: 0% → Preliminary ORR: 60% (1 CR, 8 PR, 4 SD, 2 PD) -
Slide 13: Nadunolimab and alleviation of neuropathy
Nadunolimab and alleviation of neuropathy → Chemotherapy induce neuropathy by several pathways including IL-1 (neuroinflammation) → Nadunolimab, phase 2 data in PDAC with Gem/nabP → lower Grade 3-4 peripheral neuropathy than expected from historical controls (1% vs 17%). → Further analysis from this
Slide 14: CAN10 – Opportunity in autoimmune/inflammatory disease
CAN10 – OPPORTUNITY IN AUTOIMMUNE/INFLAMMATORY DISEASE
Slide 15: CAN10 – New clinical asset in autoimmunity/inflammation
CAN10 – New clinical asset in autoimmunity/inflammation → IL1RAP-binding antibody potently blocking IL-1, IL-33 and IL-36, without ADCC → Unique anti-inflammatory activity observed in different mouse models (myocarditis, systemic sclerosis, psoriasis, inflammation) → Development focusing on systemic
Slide 16: IL1RAP and the IL-1/33/36 pathways are upregulated in SSc patient skin
IL1RAP and the IL-1/33/36 pathways are upregulated in SSc patient skin 2 publicly available human SSc cohorts show differential expression of IL1RAP and associated genes in SSc skin 14 SSc vs. 11 healthy Agilent 2-channel Mahoney et al. 2015 GSE59787 Microarray Skaug et al. Ann Rheum Dis 2020. GSE13
Slide 17: Systemic sclerosis: mCAN10 inhibits bleomycin-induced skin fibrosis
Systemic sclerosis: mCAN10 inhibits bleomycin-induced skin fibrosis Bleomycin (BLM) model mCAN10 10 mg/kg twice W BLM 2.5 mg/kg (daily s.c.) Nintedanib 50 mg/kg QD C57BL/6 Established fibrosis Termination n=10 per group Week 3 Week 6 No BLM (6 wks) Baseline BLM (3 wks) Dermal thickness Myofibroblast
Slide 18: CAN10 first-in-human study
CAN10 first-in-human study • Combined SAD/MAD protocol • IV administration in healthy volunteers (SAD) • SC administration in subjects with mild to moderate plaque psoriasis (MAD) • Safety and PK • Building value by adding additional PD analyses - Receptor occupancy - Ex vivo inhibition assay (prote
Slide 19: Milestones & Investment Highlights
MILESTONES & INVESTMENT HIGHLIGHTS
Slide 20: Upcoming milestones
Upcoming milestones Nadunolimab Additional PDAC NSCLC TNBC CAN10 milestones • Start of Phase IIb trial • Efficacy/biomarker • Full recruitment H2 • Phase I data updates • New clinical data in 150-200 patients data from CANFOUR 2024 during 2024 (including presented from H1 2024 during 2024 safety and
Slide 21: Cantargia – Investment highlights
Cantargia – Investment highlights NOVEL IL1RAP ANTIBODIES, POTENTIAL TO TREAT CANCER & INFLAMMATORY DISEASE • IL1RAP elevated in most solid and liquid tumors • IL1RAP signaling drives several autoimmune and inflammatory diseases NADUNOLIMAB: CLEAR ACTIVITY SIGNALS IN CANCER THERAPY WITH UPCOMING CAT